Please login to the form below

Not currently logged in
Email:
Password:

antibody drug conjugate

This page shows the latest antibody drug conjugate news and features for those working in and with pharma, biotech and healthcare.

MorphoSys eyes 2020 launch for lymphoma CAR-T challenger

MorphoSys eyes 2020 launch for lymphoma CAR-T challenger

well as Roche’s CD79b-targeting antibody-drug conjugate (ADC) polatuzumab vedotin, that has already been filed in the US. ... The L-MIND data raise the likelihood of MorphoSys attracting a commercial partner for the antibody, which has been tipped as a

Latest news

More from news
Approximately 1 fully matching, plus 61 partially matching documents found.

Latest Intelligence

  • AstraZeneca’s oncology renaissance AstraZeneca’s oncology renaissance

    Finally, there are antibody drug conjugate programmes led out of MedImmune. ... The PARP inhibitor drug prevents BRCA mutation-carrying cells from repairing themselves, causing them to die.

  • Deal Watch January 2018

    enhance blood-brain barrier (BBB) penetration of antibody molecules via the transferrin receptor. ... Also in January Immunomedics sold tiered royalty rights on global net sales of its antibody drug conjugate, sacituzumab govitecan, to Royalty Pharma for

  • Pharma deals continue to slide Pharma deals continue to slide

    Roche has licensed a monoclonal antibody in phase II to Dermira, a dermatology company. ... 250+. Immunogen (US). Jazz (IE, US). Collaboration and option. Phase I haematology-related antibody-drug conjugate plus 2 other projects.

  • Deal Watch February 2017 Deal Watch February 2017

    Competitive deal tendering and investor revolt. One of the largest therapeutic deals in February was the Immunomedics licence with Seattle Genetics for a phase 2 stage antibody drug conjugate (ADC), sacituzumab ... Acquisition - company. 2, 475.

  • Deal Watch April 2016 Deal Watch April 2016

    Its lead compound, Rovalpituzumab tesirine (Rova-T), is a biomarker-specific antibody drug conjugate, in phase I/II targeting cancer stem cell protein DLL3. ... AbbVie (US). Company acquisition. Phase I antibody drug conjugate targeting cancer stem cell

More from intelligence
Approximately 0 fully matching, plus 16 partially matching documents found.

Latest appointments

  • Glythera strengthens its scientific advisory board and appoints CSO Glythera strengthens its scientific advisory board and appoints CSO

    Glythera has appointed new chief scientific officer Dr Robert Lutz to lead the advancement of the UK-based biotech's antibody drug conjugate portfolio.

  • Glythera appoints Dr Mike Owen Glythera appoints Dr Mike Owen

    He joins as a non-executive director. Antibody drug conjugate development company, Glythera has appointed Dr Mike Owen as its non-executive director. ... At GSK, Owen was responsible for initiating and growing the group’s pre-clinical and clinical

  • ADC Therapeutics expands team ADC Therapeutics expands team

    Appointments preceed its first antibody drug conjugate trials. ADC Therapeutics has significantly expanded its team head of putting its first antibody drug conjugates (ADCs) into clinical development. ... Oncology drug development company's new team

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

The Exhibition Hall: Past, Present and Future
As I sit here at another pharma conference, I start to reflect on how they have changed over the years....
Success breeds success
This week we received the exciting news that we have been shortlisted for the Times Business Awards 2019, Tunbridge Wells in the 'Best Business 1-25 Employees' category....
Turning learning into action: The challenge of behaviour change
...

Infographics